All News

Found 72,053 articles

• Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  9/27/2023

  Lyell Immunopharma, Inc. announced that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer taking place in San Diego, Nov. 1-5, 2023.

• CTL Amedica Secures ECAT Approval from U.S. Defense Logistics Agency

  9/27/2023

  CTL Amedica has secured Electronic Catalog government contract approval from the U.S. Defense Logistics Agency.

• SaNOtize’s Board Appoints Steven Basta as New Chief Executive Officer

  9/27/2023

  SaNOtize Research and Development Corp. announced that the company has appointed Steven Basta, an experienced biopharma and medical device commercial leader, as its new Chief Executive Officer.

• Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

  9/27/2023

  Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. that is developing ultra-high concentration nitric oxide as an immunotherapeutic for solid tumors, announced that the Company will present data at the upcoming Society for Immunotherapy of Cancer Annual Meeting 2023, which is scheduled to be held November 3rd – 5th at the San Diego Convention Center in San Diego, California.

• Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

  9/27/2023

  Affimed N.V. announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 1-5, 2023 in San Diego, California.

• Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)

  9/27/2023

  Scilex Holding Company submitted a request to the Securities and Exchange Commission to withdraw its Registration Statement on Form S-1, as amended, initially filed with the SEC on April 21, 2023.

• Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

  9/27/2023

  Senti Biosciences, Inc. announced four poster presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA.

• Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  9/27/2023

  Cue Biopharma, Inc. announced two poster presentations highlighting the company’s Immuno-STAT™ platform and lead clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting.

• Tonix Pharmaceuticals Announces DoD Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

  9/27/2023

  Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced that the University of North Carolina Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense to investigate the potential of Tonix’s TNX-102 SL to reduce the frequency and severity of adverse effects of acute trauma.

• Canadian Veteran Receives Approval for APEX's Psilocybin Therapy Through Health Canada's Special Access Program

  9/27/2023

  Apex Labs Ltd. (APEX or the Company) is excited to announce that a physician has been authorized to receive APEX-90 macrodose psilocybin drug product via Health Canada's Special Access Program (SAP) for the treatment of a Canadian Armed Forces Veteran suffering from Treatment Resistant Depression (TRD).

• Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results

  9/27/2023

  Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.

• CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL

  9/27/2023

  Cantex Pharmaceuticals, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial.

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - September 27, 2023

  9/27/2023

  Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved “inducement” grants to 47 new employees under Rule 5635 of the NASDAQ Listing Rules.

• QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report

  9/27/2023

  QIAGEN announced the release of its Sustainability Report 2022, emphasizing its unwavering focus on driving positive change for society through its goals for Environment, Social and Governance metrics.

• MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

  9/27/2023

  MediciNova, Inc. announced the results of the nonclinical studies conducted under its contract with the BARDA, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.

• Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations

  9/27/2023

  Biophytis SA publishes its half-year accounts as of 30 June 2023 and provides an update on the progress of its R&D projects over the 1st half of the year and the last few months.

• Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)

  9/27/2023

  Viatris Inc. and Ocuphire Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™.

• Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases

  9/27/2023

  Twist Bioscience Corporation and IMIDomics, Inc. today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.

• Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

  9/27/2023

  Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG"). 

• Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

  9/27/2023

  Gritstone bio, Inc. announced that it was awarded a contract by the Biomedical Advanced Research and Development Authority to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA vaccine candidate containing Spike plus other viral targets to protect against COVID-19.